Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control of blood sugar levels than Sanofi’s Toujeo ...
The company said it has decided to stop distributing its once-daily basal insulin Tresiba (insulin degludec) in Germany - Europe's largest pharmaceutical market - in the wake of a "negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback